Neumora Therapeutics(NMRA) Prnewswire·2025-02-25 10:45Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Neumora Therapeutics, Inc. [2] - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant [3]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant improvement in treating Major Depressive Disorder (MDD) and the addition of a prespecified analysis that lacked adequate data [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].